Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Eur J Immunol

Retrieve available abstracts of 12 articles:
HTML format



Single Articles


    November 2020
  1. BRANDL C, Angermuller S, Nitschke L
    Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy.
    Eur J Immunol. 2020;50:1834-1837.
    PubMed    


    May 2020
  2. ZHAO XY, Jiang Q, Jiang H, Hu LJ, et al
    Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
    Eur J Immunol. 2020 May 1. doi: 10.1002/eji.201948375.
    PubMed     Abstract available


    March 2020
  3. KAISER TK, Li H, Rossmann L, Reichardt SD, et al
    Glucocorticoids delivered by inorganic-organic hybrid nanoparticles mitigate acute graft-versus-host disease and sustain graft-versus-leukemia activity.
    Eur J Immunol. 2020 Mar 4. doi: 10.1002/eji.201948464.
    PubMed     Abstract available


    November 2019
  4. SWATLER J, Dudka W, Bugajski L, Brewinska-Olchowik M, et al
    Chronic myeloid leukemia-derived extracellular vesicles increase Foxp3 level and suppressive activity of thymic regulatory T cells.
    Eur J Immunol. 2019 Nov 23. doi: 10.1002/eji.201848051.
    PubMed    


    March 2019
  5. AMES PR, Merashli M, Gentile F
    Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
    Eur J Immunol. 2019 Mar 20. doi: 10.1002/eji.201848042.
    PubMed    


    November 2018
  6. WEHRSTEDT S, Kubis J, Zimmermann A, Bruns H, et al
    The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T-cell function.
    Eur J Immunol. 2018;48:1892-1903.
    PubMed     Abstract available


    October 2018
  7. URI A, Luhder F, Kerkau T, Beyersdorf N, et al
    During acute Graft versus Host Disease CD28 deletion in donor CD8(+) , but not CD4(+) , T cells maintains anti-leukemia responses in mice.
    Eur J Immunol. 2018 Oct 15. doi: 10.1002/eji.201847669.
    PubMed     Abstract available


    September 2018
  8. GRUNBERG M, Quandt D, Cynis H, Demuth HU, et al
    Kallikrein-related peptidases are activators of the CC chemokine CCL14.
    Eur J Immunol. 2018;48:1592-1594.
    PubMed     Abstract available


    July 2018
  9. ZOU Y, Luo W, Guo J, Luo Q, et al
    NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
    Eur J Immunol. 2018 Jul 31. doi: 10.1002/eji.201847550.
    PubMed     Abstract available


    May 2018
  10. MATKO S, Manderla J, Bonsack M, Schmitz M, et al
    PRAME peptide-specific CD8(+) T cells represent the predominant response against leukemia-associated antigens (LAAs) in healthy individuals.
    Eur J Immunol. 2018 May 8. doi: 10.1002/eji.201747399.
    PubMed     Abstract available


    April 2018
  11. SONG Y, Hu B, Liu Y, Jin Z, et al
    IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
    Eur J Immunol. 2018;48:670-682.
    PubMed     Abstract available


    February 2018
  12. EWEN EM, Pahl JHW, Miller M, Watzl C, et al
    KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
    Eur J Immunol. 2018;48:355-365.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: